Kidney Stones & Ozempic: Clinical Evidence & Safety

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Kidney stones are not formally reported as a side effect of Ozempic in FDA-approved clinical trial data. However, certain physiological changes associated with GLP-1 receptor agonists—including reduced fluid intake, weight loss, and metabolic shifts—may theoretically increase kidney stone risk in predisposed individuals. Understanding whether you fall into a higher-risk category requires medical evaluation.

Patients considering GLP-1 therapy should approach safety with precision, not assumptions. PlexusDx emphasizes personalized risk assessment: genetic factors, baseline kidney function, hydration patterns, and family history all inform whether GLP-1 treatment is appropriate and how to monitor for complications. This data-driven approach helps you and your provider make informed decisions.

What Clinical Trials Actually Show About GLP-1 and Kidney Health

Phase 3 clinical trials for semaglutide and tirzepatide did not identify kidney stones as a primary adverse event. Rare kidney-related complications reported include acute kidney injury in patients with severe dehydration or pre-existing renal disease. The connection to stones specifically remains primarily theoretical and linked to indirect risk factors rather than the drug itself.

Key trials monitored renal function via creatinine and eGFR. Most patients showed stable or improved kidney markers. However, individual variation exists: patients with low baseline eGFR, chronic kidney disease, or conditions predisposing to stone formation warrant closer scrutiny and provider oversight before initiating GLP-1 therapy.

Dehydration and Metabolic Changes: The Indirect Risk Pathway

GLP-1 agonists slow gastric emptying and reduce appetite, which can lead to decreased overall fluid and nutrient intake if patients do not deliberately maintain hydration. Dehydration concentrates urine, elevating the risk of crystal formation—a known mechanism for kidney stone development. This is an indirect effect, not a direct pharmacological action of the drug.

Risk Factor	Mechanism	How It May Relate to Kidney Stones	Mitigation Strategy
Reduced fluid intake	Appetite suppression from GLP-1 action	Concentrated urine increases stone formation risk	Intentional daily hydration monitoring (aim for pale urine color)
Rapid weight loss	Increased fat and protein mobilization	Higher uric acid and calcium excretion	Gradual dose escalation; provider-recommended electrolyte checks
Low-carb diet adoption	Common dietary choice with GLP-1 use	May increase purine and uric acid levels	Balanced macronutrient intake; discuss diet with provider or dietitian
Pre-existing renal disease	Baseline kidney dysfunction	Already elevated stone risk; GLP-1 may worsen concentration	Baseline kidney function testing; possible GLP-1 avoidance

Who Is at Higher Risk and Needs Additional Monitoring

Patients with a personal or family history of kidney stones, chronic kidney disease (eGFR below 60), recurrent urinary tract infections, or gout carry elevated baseline risk. These individuals should undergo renal function testing and a detailed stone history before starting any GLP-1 agent. Your provider may recommend adjusted dosing, enhanced hydration protocols, or alternative therapies.

Certain genetic variants associated with stone formation or uric acid metabolism can influence individual susceptibility. Understanding your metabolic predisposition—through genetic testing and baseline bloodwork—allows your provider to establish preventive measures: targeted hydration schedules, dietary adjustments, or more frequent kidney function monitoring during treatment.

Safety Strategies and Provider Decision-Making Framework

Before initiating GLP-1 therapy, a comprehensive safety evaluation should include baseline serum creatinine, eGFR, uric acid, and calcium levels. A detailed personal and family history of kidney stones, gout, or renal disease is essential. Providers may order imaging if stone history is significant. This baseline data informs whether GLP-1 is appropriate and guides monitoring frequency.

During treatment, maintain consistent hydration (most providers recommend 8–10 cups daily), monitor urine color, report any flank pain or urinary symptoms immediately, and attend scheduled kidney function checks. If you develop signs of kidney stones—severe back or side pain, painful urination, or blood in urine—seek emergency care. Open communication with your provider about dietary changes, supplement use, and hydration habits is crucial for safe GLP-1 use.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test can help provide context about your genetic predispositions in GLP-1 receptor and metabolic pathways. Key variants related to weight regulation and metabolic response may indirectly inform your provider about expected physiological changes and whether enhanced kidney monitoring is warranted. This information should be interpreted with a qualified healthcare provider alongside clinical evaluation.

The genetic test reveals predispositions in peptide-related pathways—including GLP1R and MC4R variants—that influence how your body responds to GLP-1 therapy and metabolic stress. However, the test does not predict exact medication response or guarantee kidney stone risk. It provides one layer of personalization that, combined with blood work and clinical history, supports a more comprehensive safety assessment.

Discussing your genetic insights with your provider can support a more informed conversation about whether GLP-1 is right for you, what hydration and monitoring protocols make sense, and whether additional baseline testing is necessary. This precision-wellness approach reduces guesswork and helps you start treatment confidently.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.